10/27/2020 9:05:51 PM
Mirati Therapeutics Prices Underwritten Public Offering Of 4.34 Mln Shares At $202.00/shr
9/18/2020 8:01:43 AM
Mirati Announces Updated Clinical Results From Phase 2 Study Evaluating Sitravatinib In Combination With Nivolumab
8/13/2020 8:40:00 AM
Strata Oncology Announces Partnership To Broaden Enrollment In Mirati' Trial Of MRTX849
5/18/2020 4:16:53 PM
Mirati Therapeutics Appoints Joseph Leveque As Chief Medical Officer
5/15/2020 9:01:42 AM
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics
2/25/2020 8:13:29 AM
Mirati Therapeutics Q4 Net Loss $72.4 Mln Or $1.83/Shr Vs Loss Of $28.3 Mln Or $0.87/Shr Last Year
2/19/2020 8:37:08 AM
Mirati Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
1/14/2020 4:02:44 PM
Mirati Therapeutics Closes Public Offering Of 3.54 Mln Shares Of Its Common Stock
1/9/2020 10:06:24 PM
Mirati Therapeutics Prices Underwritten Public Offering Of 3.08 Mln Shares At $97.50/shr
1/8/2020 4:07:31 PM
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
8/15/2019 4:35:20 PM
Mirati Therapeutics Appoints Jenny Gizzi As VP, Human Resources